REGN
REGN
Regeneron Pharmaceuticals, Inc.
$717.85
-$2.03 (-0.28%)
Mkt Cap: $73.95B
Home / REGN / Financial Statements

Regeneron Pharmaceuticals, Inc. (REGN) Financial Statements

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Metric TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue
$14.92B
$14.34B ↑1.0%
$14.20B ↑8.3%
$13.12B ↑7.8%
$12.17B ↓24.3%
$16.07B
Cost of Revenue
$2.31B
$2.10B ↑6.6%
$1.97B ↓12.2%
$2.24B ↑31.6%
$1.71B ↓37.4%
$2.72B
Gross Profit
$12.61B
$12.24B ↑0.1%
$12.23B ↑12.5%
$10.87B ↑3.9%
$10.47B ↓21.6%
$13.35B
R&D Expenses
$6.26B
$5.85B ↑11.8%
$5.23B ↑31.3%
$3.99B ↑30.5%
$3.06B ↑16.6%
$2.62B
SG&A Expenses
$2.71B
$2.70B ↓8.6%
$2.95B ↑16.3%
$2.54B ↑20.0%
$2.12B ↑15.9%
$1.82B
Operating Income
$3.63B
$3.58B ↓10.3%
$3.99B ↓8.2%
$4.35B ↓19.3%
$5.39B ↓39.8%
$8.95B
Interest Expense
$48.00M
$43.80M ↓20.7%
$55.20M ↓24.4%
$73.00M ↑22.9%
$59.40M ↑3.7%
$57.30M
Income Tax
$733.50M
$725.80M ↑97.6%
$367.30M ↑49.5%
$245.70M ↓52.8%
$520.40M ↓58.4%
$1.25B
Net Income
$4.42B
$4.50B ↑2.1%
$4.41B ↑11.6%
$3.95B ↓8.9%
$4.34B ↓46.3%
$8.08B
EBITDA
$5.74B
$5.82B ↑9.4%
$5.32B ↑13.3%
$4.69B ↓10.8%
$5.26B ↓45.6%
$9.67B
EPS
41.04
41.48 ↑8.2%
38.34 ↑10.3%
34.77 ↓9.0%
38.22 ↓46.9%
71.97
Shares Out (Diluted)
431.00M
108.60M ↓5.6%
115.10M ↑1.2%
113.70M ↑0.2%
113.50M ↑1.2%
112.20M